Immunotherapy boosts responses in hormone receptor-positive breast cancers
- PMID: 39901048
- DOI: 10.1038/s41591-024-03441-5
Immunotherapy boosts responses in hormone receptor-positive breast cancers
Conflict of interest statement
Competing interests: Z.M. is on the advisory board for or consults for Gilead Sciences, Daiichi Sankyo, AstraZeneca, Lilly Medical, Merck, Pfizer and Novartis. K.A.G. is on the advisory board for or consults for Pfizer, Novartis, Astra Zeneca, Eli Lilly, Merck, Gilead Sciences, Celcuity and City of Hope.
References
-
- Loi, S. et al. Nat. Med. https://doi.org/10.1038/s41591-024-03414-8 (2025). - DOI - PubMed
-
- Cardoso, F. et al. Nat. Med. https://doi.org/10.1038/s41591-024-03415-7 (2025). - DOI - PubMed
LinkOut - more resources
Full Text Sources